Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update

Priya Patel, Paula D. Robinson, Jennifer Thackray, Jacqueline Flank, Mark T. Holdsworth, Paul Gibson, Andrea Orsey, Carol Portwine, Jason Freedman, Jennifer R. Madden, Robert Phillips, Lillian Sung, L. Lee Dupuis*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


This update of the 2013 clinical practice guideline provides clinicians with guidance regarding the use of aprepitant and palonosetron for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) in children. The recommendations were based on three systematic reviews. Substantive changes were made to the guideline recommendations including the inclusion of palonosetron to the 5-HT3 antagonists recommended for children receiving highly emetogenic chemotherapy (HEC) and the recommendation of aprepitant for children 6 months of age or older receiving HEC. To optimize CINV control in children, future work must focus on closing critical research gaps.

Original languageEnglish
Article numbere26542
Number of pages12
JournalPediatric Blood and Cancer
Issue number10
Early online date28 Apr 2017
Publication statusPublished - 1 Oct 2017

Bibliographical note

© 2017 Wiley Periodicals, Inc. This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details.


  • chemotherapy
  • guideline
  • nausea
  • pediatrics
  • supportive care
  • vomiting
  • Quinuclidines/therapeutic use
  • Serotonin Antagonists/therapeutic use
  • Nausea/chemically induced
  • Humans
  • Child, Preschool
  • Neoplasms/drug therapy
  • Infant
  • Male
  • Palonosetron
  • Vomiting/chemically induced
  • Isoquinolines/therapeutic use
  • Adolescent
  • Female
  • Child
  • Practice Guidelines as Topic

Cite this